Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Basso

Showing results (221-230 of 379) with videos related to

Pageof 38
Sort By:
Haematologica|December 7, 2014
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangementMartina Pigazzi, Elena Manara, Barbara Buldini, et al.
Cytometry. Part B, Clinical Cytometry|June 24, 2015
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemiaFrancesco Cavazzini, Diana Campioni, Luisa Ferrari, et al.
British Journal of Haematology|January 24, 2018
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemiaFederica Lovisa, Marco Zecca, Bartolomeo Rossi, et al.
Pediatric Blood & Cancer|December 19, 2018
Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000Angela Schumich, Margarita Maurer-Granofszky, Andishe Attarbaschi, et al.
Haematologica|May 24, 2015
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemiaLeonid Karawajew, Michael Dworzak, Richard Ratei, et al.
British Journal of Haematology|June 8, 2004
Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating markerSuzanne McElwaine, Claire Mulligan, Jürgen Groet, et al.
Cell Reports|September 28, 2022
FOXA1 regulates alternative splicing in prostate cancerMarco Del Giudice, John G Foster, Serena Peirone, et al.
Journal of Medicinal Chemistry|August 12, 2009
2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerizationRomeo Romagnoli, Pier Giovanni Baraldi, Maria Dora Carrion, et al.
Oncotarget|July 16, 2014
Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcomeGloria Milani, Paola Rebora, Benedetta Accordi, et al.
Cytometry. Part B, Clinical Cytometry|June 13, 2008
Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasibleMichael Norbert Dworzak, Giuseppe Gaipa, Richard Ratei, et al.
Pageof 38

Showing results (221-230 of 379) with videos related to

Sort By:
Pageof 38
Haematologica|December 7, 2014
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangementMartina Pigazzi, Elena Manara, Barbara Buldini, et al.
Cytometry. Part B, Clinical Cytometry|June 24, 2015
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemiaFrancesco Cavazzini, Diana Campioni, Luisa Ferrari, et al.
British Journal of Haematology|January 24, 2018
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemiaFederica Lovisa, Marco Zecca, Bartolomeo Rossi, et al.
Pediatric Blood & Cancer|December 19, 2018
Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000Angela Schumich, Margarita Maurer-Granofszky, Andishe Attarbaschi, et al.
Haematologica|May 24, 2015
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemiaLeonid Karawajew, Michael Dworzak, Richard Ratei, et al.
British Journal of Haematology|June 8, 2004
Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating markerSuzanne McElwaine, Claire Mulligan, Jürgen Groet, et al.
Cell Reports|September 28, 2022
FOXA1 regulates alternative splicing in prostate cancerMarco Del Giudice, John G Foster, Serena Peirone, et al.
Journal of Medicinal Chemistry|August 12, 2009
2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerizationRomeo Romagnoli, Pier Giovanni Baraldi, Maria Dora Carrion, et al.
Oncotarget|July 16, 2014
Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcomeGloria Milani, Paola Rebora, Benedetta Accordi, et al.
Cytometry. Part B, Clinical Cytometry|June 13, 2008
Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasibleMichael Norbert Dworzak, Giuseppe Gaipa, Richard Ratei, et al.
Pageof 38